- Home
- RR vs AARD Comparison
RR vs AARD Comparison
Compare RR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RR
- AARD
- Stock Information
- Founded
- RR 2016
- AARD 2017
- Country
- RR United States
- AARD United States
- Employees
- RR N/A
- AARD N/A
- Industry
- RR
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- RR
- AARD Health Care
- Exchange
- RR Nasdaq
- AARD Nasdaq
- Market Cap
- RR 253.6M
- AARD 216.6M
- IPO Year
- RR 2023
- AARD 2025
- Fundamental
- Price
- RR $2.00
- AARD $7.42
- Analyst Decision
- RR
- AARD Strong Buy
- Analyst Count
- RR 0
- AARD 4
- Target Price
- RR N/A
- AARD $31.50
- AVG Volume (30 Days)
- RR 9.6M
- AARD 122.4K
- Earning Date
- RR 05-14-2025
- AARD 01-01-0001
- Dividend Yield
- RR N/A
- AARD N/A
- EPS Growth
- RR N/A
- AARD N/A
- EPS
- RR N/A
- AARD N/A
- Revenue
- RR $4,391,000.00
- AARD N/A
- Revenue This Year
- RR N/A
- AARD N/A
- Revenue Next Year
- RR N/A
- AARD N/A
- P/E Ratio
- RR N/A
- AARD N/A
- Revenue Growth
- RR N/A
- AARD N/A
- 52 Week Low
- RR $0.30
- AARD $6.79
- 52 Week High
- RR $5.20
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- RR 46.96
- AARD N/A
- Support Level
- RR $1.37
- AARD N/A
- Resistance Level
- RR $2.65
- AARD N/A
- Average True Range (ATR)
- RR 0.30
- AARD 0.00
- MACD
- RR 0.03
- AARD 0.00
- Stochastic Oscillator
- RR 37.16
- AARD 0.00
About RR Richtech Robotics Inc. Class B
Richtech Robotics Inc is a developer of new robotic technologies focused on transforming labor-intensive services in hospitality and other sectors currently experiencing unprecedented labor shortages. The company designs, manufacture and sells robots to restaurants, hotels, senior living centers, casinos, factories, movie theaters and other businesses. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company designs its robots to be friendly, customizable to client environments, and extremely reliable.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.